Work

647 POSTER A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer

Year: 2006

Type: conference-abstract

Source: European Journal of Cancer Supplements

DOI: 10.1016/s1359-6349(06)70652-8

Authors: R. Cohen, D. Camidge, S. Diab, L. Gore, L. Chow, C. O'Bryant, E. Temmer, F. Fox, H. Youssoufian, S. Eckhardt

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2052406283

Cites:

Cited by: 3

Related to: 10